PARP1 and ovarian carcinoma: In ovarian cancer, a recent study by Guo et al. also demonstrated the involvement of RECQL4 in cisplatin resistance and that suppression of RECQL4 resulted in sensitivity to cisplatin and PARP inhibitor, olaparib [72].